Top

Journal of Gastrointestinal Surgery

Published in:

01-04-2012 | Original Article

High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection

Authors: Xiangjiu Ding, Kexin Wang, Hui Wang, Guangyong Zhang, Yajing Liu, Qingyun Yang, Weijie Chen, Sanyuan Hu

Published in: Journal of Gastrointestinal Surgery | Issue 4/2012

Abstract

Introduction

Chemokine ligand 20 (CCL20) plays an important role in the carcinogenesis, invasion, and progression of malignancies. This study aimed to investigate the prognostic significance of CCL20 in patients with hepatocellular carcinoma (HCC) after curative resection.

Methods

Expression of CCL20 was evaluated by immunohistochemistry in tumor tissue from 125 patients who underwent curative resection of HCC. The relationship between CCL20 expression and clinicopathologic features was analyzed. Univariate and multivariate analyses were performed to evaluate its predictive value for tumor recurrence and survival of HCC patients.

Results

CCL20 expression was verified in all tumor specimens. CCL20 expression was associated with tumor size (P = 0.002), tumor number (P = 0.031), vascular invasion (P = 0.003), tumor differentiation (P = 0.024), and tumor recurrence (P < 0.001). Patients with high CCL20 expression had poorer recurrence-free survival and overall survival (both P < 0.001) than those with low CCL20 expression. Multivariate analysis showed CCL20 expression was an independent predictor of tumor recurrence (Hazard ratio 3.934, P = 0.002), recurrence-free survival (Hazard ratio 2.573, P = 0.001), and overall survival (Hazard ratio 2.930, P = 0.001).

Conclusion

CCL20 expression was associated with tumor recurrence and survival of HCC patients. It may be used to predict prognosis of patients with HCC and may be a new target of postoperative adjuvant therapy.

Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533–43.PubMedCrossRef

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–76.PubMedCrossRef

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.PubMedCrossRef

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17.PubMedCrossRef

Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007;141:196–202.PubMedCrossRef

Zhou H, Huang H, Shi J, Zhao Y, Dong Q, Jia H, Liu Y, Ye Q, Sun H, Zhu X, Fu L, Guo K, Gao D, Sun J, Yan Z, Ren N, Tang Z, Qin L. Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection. Gut 2010;59:1699–708.PubMedCrossRef

Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, Reiche JA, Hermeking H, Rizzani A, Bruns CJ, Kolligs FT, Kirchner T, Göke B, De Toni EN. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 2010;16:5529–38.PubMedCrossRef

Zhao Y, Wang X, Wang T, Hu X, Hui X, Yan M, Gao Q, Chen T, Li J, Yao M, Wan D, Gu J, Fan J, He X. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology 2011;53:493–503.PubMedCrossRef

Yuan RH, Jeng YM, Hu RH, Lai PL, Lee PH, Cheng CC, Hsu HC. Role of p53 and beta-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg 2011;15:321–9.PubMedCrossRef

10.

Hieshima K, Imai T, Opdenakker G, Van Damme J, Kusuda J, Tei H, Sakaki Y, Takatsuki K, Miura R, Yoshie O, Nomiyama H. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem 1997;272:5846–53.PubMedCrossRef

11.

Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–7.PubMedCrossRef

12.

Abiko Y, Nishimura M, Kusano K, Nakashima K, Okumura K, Arakawa T, Takuma T, Mizoguchi I, Kaku T. Expression of MIP-3alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma. Arch Oral Biol 2003;48:171–5.PubMedCrossRef

13.

Ghadjar P, Rubie C, Aebersold DM, Keilholz U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer 2009;125:741–5.PubMedCrossRef

14.

Rubie C, Frick VO, Ghadjar P, Wagner M, Grimm H, Vicinus B, Justinger C, Graeber S, Schilling MK. CCL20/CCR6 expression profile in pancreatic cancer. J Transl Med 2010;8:45.PubMedCrossRef

15.

Chang KP, Hao SP, Chang JH, Wu CC, Tsang NM, Lee YS, Hsu CL, Ueng SH, Liu SC, Liu YL, Wei PC, Liang Y, Chang YS, Yu JS. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res 2008;14:6979–87.PubMedCrossRef

16.

Wallace AE, Catalano RD, Anderson RA, Jabbour HN. Chemokine (C-C) motif ligand 20 is regulated by PGF(2alpha)-F-prostanoid receptor signalling in endometrial adenocarcinoma and promotes cell proliferation. Mol Cell Endocrinol 2011;331:129–35.PubMedCrossRef

17.

Beider K, Abraham M, Begin M, Wald H, Weiss ID, Wald O, Pikarsky E, Abramovitch R, Zeira E, Galun E, Nagler A, Peled A. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One 2009;4:e5125.PubMedCrossRef

18.

Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3alpha in hepatocellular carcinoma: relationship with clinical factors and prognostic importance during therapy. Int J Mol Med 2003;11:601–5.PubMed

19.

Fujii H, Itoh Y, Yamaguchi K, Yamauchi N, Harano Y, Nakajima T, Minami M, Okanoue T. Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro. Biochem Biophys Res Commun 2004;322:1052–8.PubMedCrossRef

20.

Rubie C, Frick VO, Wagner M, Rau B, Weber C, Kruse B, Kempf K, Tilton B, König J, Schilling M. Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand J Immunol 2006;63:468–77.PubMedCrossRef

21.

Rubie C, Frick VO, Wagner M, Weber C, Kruse B, Kempf K, König J, Rau B, Schilling M. Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases. World J Gastroenterol 2006;12:6627–33.PubMed

22.

Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, Taylor BR, Grant DR, Vollmer CM. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 2006;202:275–83.PubMedCrossRef

23.

Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu YF, Zhou J, Zhang BH, Fan J. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009;9:418.PubMedCrossRef

24.

Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, Ren N, Zhuang PY, Zhu XD, Fan J, Tang ZY. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 2007;47:684–90.PubMedCrossRef

25.

Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586–93.PubMedCrossRef

26.

Wang D, Xu MR, Wang T, Li T, Zhu J. MTSS1 overexpression correlates with poor prognosis in colorectal cancer. J Gastrointest Surg 2011;15:1205–12.PubMedCrossRef

27.

Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008;60:401–7.PubMedCrossRef

28.

Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, Wong J. Prediction of Posthepatectomy Recurrence of Hepatocellular Carcinoma by Circulating Cancer Stem Cells: A Prospective Study. Ann Surg doi:10.1097/SLA.0b013e3182300a1d. [Online September 1, 2011]

29.

Brand S, Olszak T, Beigel F, Diebold J, Otte JM, Eichhorst ST, Göke B, Dambacher J. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem 2006;97:709–23.PubMedCrossRef

30.

Ghadjar P, Loddenkemper C, Coupland SE, Stroux A, Noutsias M, Thiel E, Christoph F, Miller K, Scheibenbogen C, Keilholz U. Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol 2008;134:1181–9.PubMedCrossRef

31.

Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q, Wang H, Chen J, Wang H. Tumor-Associated Macrophages Recruit CCR6 Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice. PLoS One 2011;6:e19495.PubMedCrossRef

32.

Bonnotte B, Crittenden M, Larmonier N, Gough M, Vile RG. MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J Immunol 2004;173:4929–35.PubMed

33.

Kleeff J, Kusama T, Rossi DL, Ishiwata T, Maruyama H, Friess H, Büchler MW, Zlotnik A, Korc M. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer 1999;81:650–7.PubMedCrossRef

34.

Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 2006;58:962–74.PubMedCrossRef

35.

Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 2010;46:1712–23.PubMedCrossRef

36.

Fushimi T, Kojima A, Moore MA, Crystal RG. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 2000;105:1383–93.PubMedCrossRef

Title: High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection
Authors: Xiangjiu Ding
Kexin Wang
Hui Wang
Guangyong Zhang
Yajing Liu
Qingyun Yang
Weijie Chen
Sanyuan Hu
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 4/2012
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-011-1775-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2012

Robotic Anterior RAMPS in Well-Selected Left-Sided Pancreatic Cancer

Counterclockwise Rotation of Roux-En-Y Limb Significantly Reduces Internal Herniation in Laparoscopic Roux-En-Y Gastric Bypass (LRYGB)

Extensive Mediastinal Lymphadenectomy During Minimally Invasive Esophagectomy: Optimal Results from a Single Center

Intraoperative Detection of Disappearing Colorectal Liver Metastases as a Predictor of Residual Disease

Timing and Risk Factors of Hepatectomy in the Management of Complications Following Laparoscopic Cholecystectomy

A Method for Early Diagnosis and Treatment of Intrathoracic Esophageal Anastomotic Leakage: Prophylactic Placement of a Drainage Tube Adjacent to the Anastomosis